Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports
This large-scale data-analytic study compared the semantic similarity of psychoactive trip reports (n≈15,000) and narrative accounts Near-Death Experiences (n=625), and found that ketamine (followed by salvinorin A and DMT) bared the most resemblance to the experience of 'dying'. The authors speculate that a ketamine model of Near-Death Experiences may indicate a neuroprotective function of endogenous NMDA antagonists released in the proximity of death.
Authors
- Enzo Tagliazucchi
- Claudio Pallavicini
- Fire Erowid
Published
Abstract
Introduction
The real or perceived proximity to death often results in a non-ordinary state of consciousness characterized by phenomenological features such as the perception of leaving the body boundaries, feelings of peace, bliss and timelessness, life review, the sensation of traveling through a tunnel and an irreversible threshold. Near-death experiences (NDEs) are comparable among individuals of different cultures, suggesting an underlying neurobiological mechanism. Anecdotal accounts of the similarity between NDEs and certain drug-induced altered states of consciousness prompted us to perform a large-scale comparative analysis of these experiences.
Methods
After assessing the semantic similarity between ≈15,000 reports linked to the use of 165 psychoactive substances and 625 NDE narratives, we determined that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine consistently resulted in reports most similar to those associated with NDEs. Ketamine was followed by Salvia divinorum (a plant containing a potent and selective κ receptor agonist) and a series of serotonergic psychedelics, including the endogenous serotonin 2A receptor agonist N,N-Dimethyltryptamine (DMT).
Results
This similarity was driven by semantic concepts related to consciousness of the self and the environment, but also by those associated with the therapeutic, ceremonial and religious aspects of drug use.
Discussion
Our analysis sheds light on the longstanding link between certain drugs and the experience of “dying“, suggests that ketamine could be used as a safe and reversible experimental model for NDE phenomenology, and supports the speculation that endogenous NMDA antagonists with neuroprotective properties may be released in the proximity of death.
Research Summary of 'Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports'
Introduction
Near-death experiences (NDEs) are recurrent, cross-cultural non-ordinary states of consciousness reported in situations of real or perceived proximity to death; common features include out-of-body experiences (OBEs), feelings of peace or bliss, timelessness, life review, tunnel-like travel and passing an irreversible threshold. Previous experimental and anecdotal work has pointed to phenomenological overlaps between NDEs and certain drug-induced altered states, notably with ketamine (an NMDA receptor antagonist) and serotonergic psychedelics such as DMT, but prior studies have been limited by small samples, constrained drug selections and reliance on structured questionnaires. Martial and colleagues set out to address three related questions: whether drugs from particular pharmacological classes yield subjective reports most similar to NDE narratives; whether such similarity can be inferred from unstructured free-text reports using natural language processing; and how heterogeneity in NDE circumstances (cause of loss of consciousness, proximity to death, emotional valence) affects similarity with drug-induced states. To answer these, they retrospectively compared 625 NDE narratives with over 15,000 Erowid reports spanning 165 psychoactive substances across multiple pharmacological classes, using latent semantic analysis (LSA) and other dimensionality-reduction techniques to quantify semantic similarity between written reports.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Martial, C., Cassol, H., Charland-Verville, V., Pallavicini, C., Sanz, C., Zamberlan, F., Vivot, R. M., Erowid, F., Erowid, E., Laureys, S., Greyson, B., & Tagliazucchi, E. (2019). Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports. Consciousness and Cognition, 69, 52-69. https://doi.org/10.1016/j.concog.2019.01.011
References (30)
Papers cited by this study that are also in Blossom
Alberich, S., Martínez-Cengotitabengoa, M., López, P. et al. · Revista de Psiquiatría y Salud Mental (2017)
Albott, C. S., Lim, K. O., Forbes, M. K. et al. · Journal of Clinical Psychiatry (2018)
Barker, S., McIlhenny, E. H., Strassman, R. J. · Drug Testing and Analysis (2012)
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Bedi, G., Cecchi, G. A., Slezak, D. F. et al. · Neuropsychopharmacology (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Dakwar, E., Anerella, C., Hart, C. L. et al. · Drug and Alcohol Dependence (2014)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2013)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Forstmann, M., Sagioglou, C. · Journal of Psychopharmacology (2017)
Show all 30 referencesShow fewer
Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Kirchner, K. · Journal of Psychopharmacology (2014)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Kraehenmann, R. · Current Neuropharmacology (2017)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Lyons, T., Carhart-Harris, R. L. · Journal of Psychopharmacology (2018)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
Nichols, D. E. · Journal of Psychopharmacology (2017)
Niciu, M. J., Shovestul, B. J., Jaso, B. A. et al. · Journal of Affective Disorders (2018)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Riva-Posse, P., Reiff, C. M., Edwards, J. A. et al. · Journal of Affective Disorders (2018)
Sanz, C., Zamberlan, F., Erowid, E. et al. · Frontiers in Neuroscience (2018)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Ahmad, M., Szabo, A., Kovacs, A. et al. · Frontiers in Neuroscience (2016)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)
Cited By (6)
Papers in Blossom that reference this study
Acevedo, E. C., Uhler, S., White, K. et al. · Journal of Psychoactive Drugs (2024)
David, J., Bouso, J. C., Kohek, M. et al. · Frontiers in Psychiatry (2023)
Swee, M. B., Nayak, S., Hurwitz, E. et al. · PLOS ONE (2022)
Tagliazucchi, E. · Frontiers in Pharmacology (2022)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
Doss, M. K., May, D. G., Johnson, M. W. et al. · Scientific Reports (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.